Indication Pipeline


Keratoconus (KCN) is a progressive eye disease in which the normally round cornea thins and begins to bulge into a cone-like shape. Progression of this disease can degrade vision to a point necessitating a corneal transplant in 1 out of 5 patients1.  Once thought to be an Orphan Disease in the US, Keratoconus is now thought to affect 1:545 persons or 600,000 patients1and represents a $3B US market opportunity.  CXLens has been shown to arrest the progression of KCN. TECLens control console can drive two CXLens devices at once to treat both eyes simultaneously representing a 400% increase in clinical efficiency. No other CXL system can treat both eyes at once.

Low Myopia

Myopia (nearsightedness) is a global public health crisis. By 2050, nearly 5 billion people or 1 out of every 2 people on earth will suffer from myopia2. In the USA, myopia cases have increased 66% since 1971. Today in East and South East Asia in countries such as South Korea, Taiwan, Singapore, China and Japan the prevalence of myopia is 80-90% among urban teenagers. 96.5% of 19-year-old males in Singapore suffer from myopia.

The vast majority of myopic patients are considered low myopes (less than -3 diopters of refractive error) and wear contact lenses or glasses. CXLens was designed to accurately correct low myopia with its real-time closed loop Ultrasound dosing technology.  There are 13.5 million low myopes in the US. This segment of the US vision correction market represents an $8B opportunity.


Presbyopia is farsightedness caused by loss of elasticity of the lens of the eye with age and affects nearly everyone over the age of 40.  CXLens was designed to accurately correct presbyopia by reshaping the cornea to compensate for natural lens stiffness with its real-time closed loop Ultrasound dosing technology.  Presbyopia affects over 50 million Americans and represents a $15B opportunity.

  1. Market Scope 2018
  2. Holden, et. al.  (2016). “Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050.” Ophthalmology 123(5): 1036-1042.